Diet Shapes Muscle Aging: What the Latest Research Reveals

Skeletal muscle loss accelerates after age 40, with muscle mass declining at 0.6–1% per year and function at roughly 3% per year, culminating in sarcopenia—a condition linked to falls, institutionalization, and death. This editorial, introducing a Special Issue of Nutrients titled 'Diet and Muscle Metabolism,' synthesizes key findings across multiple studies to advance understanding of how diet and metabolism interact with aging muscle biology.

The biological underpinnings of sarcopenia are multifactorial. Chronic low-grade inflammation ('inflamm-aging'), driven by cytokines such as IL-1, IL-6, and TNF-α, promotes muscle catabolism and reduces food intake. Mitochondrial dysfunction compounds this by generating excess reactive oxygen species (ROS), which damage intracellular macromolecules and trigger innate immune activation via mitochondrial DAMPs, creating a self-reinforcing inflammatory-catabolic cycle. Structural changes—including myofiber atrophy, intermuscular fat infiltration, and gut dysbiosis—further accelerate decline. A large Italian cohort study (n=1,510) within the issue found sarcopenia as the most prevalent musculoskeletal phenotype (17%), followed by osteosarcopenia (14.7%) and sarcopenic obesity (2%), with inflammatory and nutritional biomarkers (CRP, ESR, albumin, iron) significantly associated with these conditions.

Three animal studies in the issue shed light on diet-muscle interactions. Maternal low-protein diet during lactation reduced offspring muscle mass and strength, with sex-specific trajectories—female offspring initially recovered but experienced accelerated muscle loss during aging. A comparison of high-fat/sucrose (HFS) versus ketogenic diets (KD) in rats showed the KD preserved insulin-stimulated glucose metabolism, improved mitochondrial markers, and supported muscle-type-specific ketone utilization, while the HFS diet impaired metabolic flexibility. A third study found that male rats on a high-fat/high-sucrose diet exhibited elevated mitochondrial respiration and insulin resistance compared to females, with transcriptomic analysis revealing distinct sex-dependent differences in PI3K/AKT and PPARα/RXRα signaling pathways.

On the clinical intervention front, a two-month multidisciplinary residential program (MRP) combining personalized low-energy diet, aerobic plus resistance training five days per week, and cognitive behavioral therapy significantly improved Short Physical Performance Battery (SPPB) scores, reduced fat mass and visceral adipose tissue, and improved glycemic control, lipid profiles, and insulin sensitivity in institutionalized adults with sarcopenic obesity. Beyond protein, compounds such as omega-3 PUFAs, vitamin D, creatine, and HMB show variable but generally modest benefits. Emerging nutraceuticals—resveratrol, quercetin, ursolic acid, urolithin, fisetin, and nicotinamide riboside—target autophagy, senescence, and mitochondrial biogenesis in preclinical models, though human evidence remains limited.

The editorial concludes that no pharmacological treatments currently exist for sarcopenia, making lifestyle interventions—particularly protein-rich diets combined with resistance training—the frontline approach. Personalized nutritional strategies tailored to sex, metabolic phenotype, and clinical status represent the most promising avenue forward, with pharmacological development needed for those unable to benefit from lifestyle measures.